Genasense Phase III Trial In Multiple Myeloma Fails

Genta says it will analyze the trial data “in considerably more detail before making decisions regarding the Genasense program in myeloma.” News of the failed trial comes on the heels of a separate Phase III study of oblimersen in chronic lymphocytic leukemia that met its primary endpoint but failed to show a survival benefit.